Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above

References

• World Health Organization. WHO Expert Consultation on Rabies, Second report. World Health Organ Tech Rep Ser 2013; (982):1-139, PMID:24069724.
   PubMedGoogle Scholar
• Wilde H, Lumlertdacha B, Meslin FX, Ghai S, Hemachudha T. Worldwide rabies deaths prevention–A focus on the current inadequacies in postexposure prophylaxis of animal bite victims. Vaccine 2016; 34(2):187-9; PMID:26626211; http://dx.doi.org/10.1016/j.vaccine.2015.11.036
   PubMed Web of Science ®Google Scholar
• Knobel DL, Cleaveland S, Coleman PG, Fèvre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin FX. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83(5):360-8; PMID:15976877; http://dx.doi.org/S0042-96862005000500012
   PubMed Web of Science ®Google Scholar
• Huang G, Liu H, Tang Q, Yu P, Shen X, Zhang Y, Liu X, Cao Q, Fu C, Liu B, et al. Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2–1 intramuscular regimen in healthy volunteers. Hum Vaccin Immunother 2014; 10(1):114-9; PMID:24008819; http://dx.doi.org/10.4161/hv.26264
   PubMed Web of Science ®Google Scholar
• Hu R, Tang Q, Tang J, Fooks AR. Rabies in China: an update. Vector Borne Zoonotic Dis 2009 Feb; 9(1):1-12. Epub 2008 Sep 21.Review; PMID:18803503; http://dx.doi.org/10.1089/vbz.2008.0046
   PubMed Web of Science ®Google Scholar
• Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol 2013; 4:171. Print 2013; PMID:23825474.
   PubMed Web of Science ®Google Scholar
• Dewan SK, Zheng SB, Xia SJ, Bill K. Senescent remodeling of the immune system and its contribution to the predisposition of the elderly to infections. Chin Med J (Engl) 2012; 125(18):3325-31; PMID:22964331.
   PubMed Web of Science ®Google Scholar
• Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001; 33(9):1553-66; PMID:11588700; http://dx.doi.org/10.1086/322968
   PubMed Web of Science ®Google Scholar
• Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46(7):1078-84; PMID:18444828; http://dx.doi.org/10.1086/529197
   PubMed Web of Science ®Google Scholar
• He YJ, Liu ZM, Zuo XW. Analysis and comparison of rabies vaccination effects by 5 dose immunization regimen and 2-1-1 immunization regimen. Experimental and Laboratory Medicine, 2014, 22(3):353-4.
   Google Scholar
• WHO Publication. Rabies vaccines: WHO position paper recommendations. Vaccine 2010; 28:7140-2; PMID:20831913; http://dx.doi.org/10.1016/j.vaccine.2010.08.082
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Rabies. Guide for post-exposure treatment. Eighth report. WHO technical report 824. Geneva Switzerland: World Health Organization 1992.
   Google Scholar
• Joseph J, N S, Khan AM, Rajoura OP. Determinants of delay in initiating post-exposure prophylaxis for rabies prevention among animal bite cases: hospital based study. Vaccine 2013; 32(1):74-7; PMID:24188758; http://dx.doi.org/10.1016/j.vaccine.2013.10.067
   PubMed Web of Science ®Google Scholar
• He XF, Jiang Ll. Compliance comparison of vaccination procedures of Essen and Zagreb. Zhejiang J Prevent Med 2014, 26(5):490-1.
   Google Scholar
• Wang Cl, Zhang XW, Yu YX. Study on the compliance and economic cost of rabies vaccination. Chinese J Vaccines Immu 2010, 16(3):254-7.
   Google Scholar
• Lv YQ. A Survey on the Presence of Rabies Virus and Antibody Production in Response to Inactivated Vaccines in Dogs for Changping district, Beijing. Beijing: Chinese Academy of Agricultural Sciences, 2009: 1-33.
   Google Scholar
• Liu H, Huang G, Tang Q, Li J, Cao S, Fu C, Cao Q, Liu B, Pan H, Wang M. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum Vaccin 2011; 7(2):220-4; PMID:21311216
   PubMedGoogle Scholar
• Hu Q, Liu MQ, Zhu ZG, Zhu ZR, Lu S. Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China. Hum Vaccine Immunotherapy 2014; 10:1645-9; PMID:24632727; http://dx.doi.org/10.4161/hv.28420
   PubMed Web of Science ®Google Scholar
• Ma J, Wang H, Li J, Chang L, Xie Y, Liu Z, Malerczyk C. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults. Hum Vaccine Immunotherapy 2014; 10(10):2805-12. Hum Vaccine Immunotherapy. 2015; 11(5):1295; PMID:25483635; http://dx.doi.org/10.4161/21645515.2014.972773
   PubMed Web of Science ®Google Scholar
• Li R, Li Y, Wen S, Wen H, Nong Y, Mo Z, Xie F, Pellegrini M. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study. Hum Vaccine Immunotherapy 2015; 11(2):435-42; PMID:25692350; http://dx.doi.org/10.4161/21645515.2014.994460
   PubMed Web of Science ®Google Scholar
• Li R, Huang L, Li J, Mo Z, He B, Wang Y, Wu X, Minutello M, Guinet-Morlot F, Pichon S. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China. Vaccine 2013; 31(50):5940-7; PMID:24148575; http://dx.doi.org/10.1016/j.vaccine.2013.10.043
   PubMed Web of Science ®Google Scholar